SG10201709090UA - Sobetirome in the treatment of myelination diseases - Google Patents
Sobetirome in the treatment of myelination diseasesInfo
- Publication number
- SG10201709090UA SG10201709090UA SG10201709090UA SG10201709090UA SG10201709090UA SG 10201709090U A SG10201709090U A SG 10201709090UA SG 10201709090U A SG10201709090U A SG 10201709090UA SG 10201709090U A SG10201709090U A SG 10201709090UA SG 10201709090U A SG10201709090U A SG 10201709090UA
- Authority
- SG
- Singapore
- Prior art keywords
- sobetirome
- treatment
- myelination diseases
- myelination
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819467P | 2013-05-03 | 2013-05-03 | |
| PCT/US2013/053640 WO2014178892A1 (en) | 2013-05-03 | 2013-08-05 | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| PCT/US2014/014943 WO2014178931A1 (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201709090UA true SG10201709090UA (en) | 2017-12-28 |
Family
ID=51843844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201709090UA SG10201709090UA (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
| SG11201509012QA SG11201509012QA (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509012QA SG11201509012QA (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10226438B2 (en) |
| EP (1) | EP2991670B8 (en) |
| JP (4) | JP2016517883A (en) |
| CN (1) | CN105431163A (en) |
| AU (1) | AU2014260468A1 (en) |
| BR (1) | BR112015027682A2 (en) |
| CA (1) | CA2911309A1 (en) |
| ES (1) | ES2745532T3 (en) |
| HK (1) | HK1222552A1 (en) |
| MX (2) | MX2015015228A (en) |
| RU (1) | RU2015151216A (en) |
| SG (2) | SG10201709090UA (en) |
| WO (2) | WO2014178892A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| AU2015253100B2 (en) | 2014-04-30 | 2018-01-18 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
| CA2957721C (en) | 2014-08-13 | 2021-04-13 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| EP3368088B1 (en) * | 2015-10-29 | 2023-06-07 | The Johns Hopkins University | Compositions and methods for treatment of peroxisomal disorders and leukodystrophies |
| US11351183B2 (en) | 2016-04-22 | 2022-06-07 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| CN113730421A (en) * | 2016-04-22 | 2021-12-03 | 维京治疗股份有限公司 | Use of thyroid beta agonists |
| DK3457851T3 (en) * | 2016-05-18 | 2021-09-20 | Univ Oregon Health & Science | DERIVATIVES OF SOBETIR ROOMS |
| KR102537274B1 (en) | 2016-08-12 | 2023-05-25 | 오레곤 헬스 앤드 사이언스 유니버시티 | Amide compounds, pharmaceutical compositions thereof and methods of using them |
| WO2018183940A1 (en) * | 2017-03-31 | 2018-10-04 | Neurovia, Inc. | Methods and compositions for treating niemann-pick disease |
| US11160881B2 (en) | 2017-04-27 | 2021-11-02 | The Johns Hopkins University | Dendrimer compositions for use in angiography |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US10780069B2 (en) * | 2017-05-18 | 2020-09-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of GC-1 in transplant related population |
| EP3644983B1 (en) | 2017-06-29 | 2023-10-25 | Yale University | Compositions and methods of treating or preventing fibrotic lung diseases |
| EP3656389A4 (en) * | 2017-07-18 | 2021-11-03 | Keio University | Anti-bacterial composition against th1 cell-inducing bacteria |
| EP3707193A1 (en) | 2017-11-10 | 2020-09-16 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| EP3894383A1 (en) | 2018-12-12 | 2021-10-20 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| AU2020232205A1 (en) | 2019-03-01 | 2021-10-21 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| BR112022010377A2 (en) | 2019-11-29 | 2022-10-04 | Autobahn Therapeutics Inc | NEW THYROMIMETICS |
| IL293606A (en) | 2019-12-04 | 2022-08-01 | Ashvattha Therapeutics Inc | Dendrimer compositions and methods for drug delivery to the eye |
| CN111116684B (en) * | 2019-12-31 | 2020-09-25 | 厦门甘宝利生物医药有限公司 | Liver targeting compound with thyroid hormone receptor agonist characteristic and pharmaceutical composition thereof |
| CN115569233B (en) * | 2022-10-17 | 2023-07-14 | 湖南大学 | Preparation method of high-efficiency photoinhibitor capable of absorbing light and reacting with free radical |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815221C2 (en) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli |
| DE69636677D1 (en) | 1995-12-13 | 2006-12-14 | Univ California | Crystals of ligand complexed ligand binding domain of the thyroid hormone receptor |
| JP3345428B2 (en) | 1996-08-20 | 2002-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Treatment of the eye using the synthetic thyroid forman composition |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| EP1089968B1 (en) | 1998-06-30 | 2005-04-20 | The Regents Of The University Of California | Thyroid hormone analogues and methods for their preparation |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7302347B2 (en) | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
| AU2004273986B2 (en) * | 2003-09-15 | 2010-04-22 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use in angiogenesis |
| WO2006031922A2 (en) | 2004-09-15 | 2006-03-23 | Ordway Research Institute | Thyroid hormone analogs for promoting angiogenesis |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| WO2006012015A2 (en) * | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| WO2006105205A1 (en) | 2005-03-29 | 2006-10-05 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8067375B2 (en) | 2006-10-20 | 2011-11-29 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor |
| CA2704279C (en) | 2006-11-03 | 2014-09-30 | University Of Saskatchewan | Method of treating demyelination diseases |
| FI20075245A0 (en) * | 2007-04-11 | 2007-04-11 | Markku Ahotupa | Method for the assessment of oxidative metabolism |
| PL2187882T3 (en) * | 2007-07-11 | 2013-05-31 | Medicinova Inc | Treatment of progressive neurodegenerative disease with ibudilast |
| EP2242745A1 (en) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Novel phenyl-substituted imidazolidines, method for the production thereof, medicaments containing said compounds and use thereof |
| EP2278999A4 (en) * | 2008-04-21 | 2015-04-22 | Otonomy Inc | Auris formulations for treating otic diseases and conditions |
| CN102612363A (en) | 2009-05-20 | 2012-07-25 | 舌交付有限公司 | Buccal and/or sublingual therapeutic formulation |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| AU2011343429B2 (en) | 2010-12-16 | 2016-10-20 | Sunovion Pharmaceuticals Inc. | Sublingual films |
| EP2911924B1 (en) * | 2012-10-25 | 2017-06-21 | Volvo Truck Corporation | Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system |
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
-
2013
- 2013-08-05 WO PCT/US2013/053640 patent/WO2014178892A1/en active Application Filing
- 2013-08-05 JP JP2016511718A patent/JP2016517883A/en not_active Withdrawn
-
2014
- 2014-02-05 SG SG10201709090UA patent/SG10201709090UA/en unknown
- 2014-02-05 CN CN201480038129.XA patent/CN105431163A/en active Pending
- 2014-02-05 JP JP2016511726A patent/JP6360552B6/en active Active
- 2014-02-05 US US14/888,577 patent/US10226438B2/en active Active
- 2014-02-05 BR BR112015027682A patent/BR112015027682A2/en not_active IP Right Cessation
- 2014-02-05 AU AU2014260468A patent/AU2014260468A1/en not_active Abandoned
- 2014-02-05 MX MX2015015228A patent/MX2015015228A/en unknown
- 2014-02-05 EP EP14791718.1A patent/EP2991670B8/en active Active
- 2014-02-05 CA CA2911309A patent/CA2911309A1/en not_active Abandoned
- 2014-02-05 RU RU2015151216A patent/RU2015151216A/en not_active Application Discontinuation
- 2014-02-05 SG SG11201509012QA patent/SG11201509012QA/en unknown
- 2014-02-05 ES ES14791718T patent/ES2745532T3/en active Active
- 2014-02-05 WO PCT/US2014/014943 patent/WO2014178931A1/en active Application Filing
-
2015
- 2015-10-30 MX MX2021000538A patent/MX2021000538A/en unknown
-
2016
- 2016-09-09 HK HK16110708.4A patent/HK1222552A1/en unknown
-
2018
- 2018-06-22 JP JP2018118891A patent/JP2018141024A/en active Pending
- 2018-07-23 JP JP2018137754A patent/JP2018162321A/en active Pending
-
2019
- 2019-02-13 US US16/275,117 patent/US20190175531A1/en not_active Abandoned
-
2020
- 2020-07-07 US US16/922,852 patent/US11510887B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2991670B8 (en) | 2019-09-11 |
| US20190175531A1 (en) | 2019-06-13 |
| WO2014178892A1 (en) | 2014-11-06 |
| BR112015027682A2 (en) | 2017-08-29 |
| EP2991670A1 (en) | 2016-03-09 |
| HK1222552A1 (en) | 2017-07-07 |
| WO2014178931A8 (en) | 2015-11-26 |
| ES2745532T3 (en) | 2020-03-02 |
| US20200405669A1 (en) | 2020-12-31 |
| CA2911309A1 (en) | 2014-11-06 |
| CN105431163A (en) | 2016-03-23 |
| JP6360552B6 (en) | 2018-08-15 |
| MX2021000538A (en) | 2021-04-28 |
| EP2991670B1 (en) | 2019-07-03 |
| JP2016517884A (en) | 2016-06-20 |
| EP2991670A4 (en) | 2017-01-18 |
| JP2018162321A (en) | 2018-10-18 |
| WO2014178931A1 (en) | 2014-11-06 |
| WO2014178892A8 (en) | 2015-12-17 |
| AU2014260468A1 (en) | 2015-11-19 |
| MX2015015228A (en) | 2016-10-03 |
| RU2015151216A (en) | 2017-06-08 |
| JP2018141024A (en) | 2018-09-13 |
| US11510887B2 (en) | 2022-11-29 |
| SG11201509012QA (en) | 2015-11-27 |
| JP2016517883A (en) | 2016-06-20 |
| JP6360552B2 (en) | 2018-07-18 |
| US20160081955A1 (en) | 2016-03-24 |
| US10226438B2 (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1222552A1 (en) | Sobetirome in the treatment of myelination diseases | |
| IL286759A (en) | Therapeutic methods and compositions | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| GB201321743D0 (en) | Therapeutic agents | |
| IL239368A0 (en) | Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases | |
| GB201321729D0 (en) | Therapeutic agents | |
| GB201321733D0 (en) | Therapeutic agents | |
| GB201321728D0 (en) | Therapeutic agents | |
| GB201321730D0 (en) | Therapeutic agents | |
| GB201321732D0 (en) | Therapeutic agents | |
| GB201321734D0 (en) | Therapeutic Agents | |
| HK1215164A1 (en) | Treatment methods | |
| EP2967062A4 (en) | Desethylhydroxychloroquine for the treatment of diseases associated with inflammation | |
| GB201321735D0 (en) | Therapeutic Agents | |
| GB201321745D0 (en) | Therapeutic agents | |
| ZA201500547B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| GB201321731D0 (en) | Therapeutic agents | |
| GB201308440D0 (en) | Therapeutic | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| GB201321749D0 (en) | Therapeutic agents | |
| PL2872176T3 (en) | Carboranylporphyrins for use in the treatment of cancer | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| GB201318668D0 (en) | Sonosensitive therapeutic | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| PL3079684T3 (en) | Compositions and methods for the treatment of diseases related to the renin-angiotensin-system |